文献速递临床试验与 GCP

德谷胰岛素与甘精胰岛素U100对2型糖尿病患者低血糖的影响:SWITCH 2随机临床试验

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

SWITCH 2随机双盲交叉试验纳入721例既往使用基础胰岛素且至少1项低血糖危险因素的2型糖尿病成人患者,在152个美国中心比较德谷胰岛素与甘精胰岛素U100。维持期德谷胰岛素总体症状性低血糖发生率为185.6 vs 265.4次/100患者年暴露(率比0.70,95%CI 0.61-0.80;P<.001),夜间症状性低血糖为55.2 vs 93.6次/100患者年暴露(率比0.58,95%CI 0.46-0.74;P<.001)。

要点

  • 维持期德谷胰岛素总体症状性低血糖发生率显著低于甘精胰岛素U100(率比0.70)。
  • 维持期夜间症状性低血糖发生率德谷胰岛素显著低于甘精胰岛素U100(率比0.58)。
  • 维持期严重低血糖比例两组无显著差异(1.6% vs 2.4%,McNemar P=.35)。

核心结论

  • 在既往使用胰岛素且至少1项低血糖危险因素的2型糖尿病患者中,32周德谷胰岛素治疗较甘精胰岛素U100降低了总体症状性低血糖发生率。

研究设计与样本

  • 随机双盲、 treat-to-target 交叉试验,含两个32周治疗期,每期包括16周剂量调整期和16周维持期。
  • 2014年1月至2015年12月在152个美国中心纳入721例成人2型糖尿病患者,既往使用基础胰岛素联合或不联合口服降糖药,且至少1项低血糖危险因素。
  • 患者按1:1随机接受德谷胰岛素后甘精胰岛素U100(n=361)或甘精胰岛素U100后德谷胰岛素(n=360),每个治疗序列内再按1:1随机分配早晨或晚间给药。
  • 721例随机患者平均(标准差)年龄61.4(10.5)岁,男性占53.1%,580例(80.4%)完成试验。

主要发现

  • 维持期总体症状性低血糖发生率德谷胰岛素 vs 甘精胰岛素U100为185.6 vs 265.4次/100患者年暴露(率比=0.70,95%CI 0.61-0.80;P<.001;差值-23.66次/100患者年暴露,95%CI -33.98至-13.33)。
  • 维持期发生低血糖的患者比例德谷胰岛素 vs 甘精胰岛素U100为22.5% vs 31.6%(差值-9.1%,95%CI -13.1%至-5.0%)。
  • 维持期夜间症状性低血糖发生率德谷胰岛素 vs 甘精胰岛素U100为55.2 vs 93.6次/100患者年暴露(率比=0.58,95%CI 0.46-0.74;P<.001;差值-7.41次/100患者年暴露,95%CI -11.98至-2.85)。
  • 维持期发生夜间低血糖的患者比例德谷胰岛素 vs 甘精胰岛素U100为9.7% vs 14.7%(差值-5.1%,95%CI -8.1%至-2.0%)。
  • 维持期发生严重低血糖的患者比例德谷胰岛素 vs 甘精胰岛素U100为1.6%(95%CI 0.6%-2.7%) vs 2.4%(95%CI 1.1%-3.7%)(McNemar P=.35;风险差-0.8%,95%CI -2.2%至0.5%)。

关键数值与推荐

  • 主要终点为维持期总体症状性低血糖(严重或血糖确证<56 mg/dL)发生率。
  • 次要终点为维持期夜间症状性低血糖(严重或血糖确证,发生于凌晨12:01至5:59)发生率和严重低血糖患者比例。
  • 全治疗期亦观察到德谷胰岛素 vs 甘精胰岛素U100总体及夜间症状性低血糖的统计学显著降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypoglycemia, a serious risk for insulin-treated patients with type 2 diabetes, negatively affects glycemic control. OBJECTIVE: To test whether treatment with basal insulin degludec is associated with a lower rate of hypoglycemia compared with insulin glargine U100 in patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, treat-to-target crossover trial including two 32-week treatment periods, each with a 16-week titration period and a 16-week maintenance period. The trial was conducted at 152 US centers between January 2014 and December 2015 in 721 adults with type 2 diabetes and at least 1 hypoglycemia risk factor who were previously treated with basal insulin with or without oral antidiabetic drugs. INTERVENTIONS: Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 361) or to receive insulin glargine U100 followed by insulin degludec (n = 360) and randomized 1:1 to morning or evening dosing within each treatment sequence. MAIN OUTCOMES AND MEASURES: The primary end point was the rate of overall symptomatic hypoglycemic episodes (severe or blood glucose confirmed [<56 mg/dL]) during the maintenance period. Secondary end points were the rate of nocturnal symptomatic hypoglycemic episodes (severe or blood glucose confirmed, occurring between 12:01 am and 5:59 am) and the proportion of patients with severe hypoglycemia during the maintenance period. RESULTS: Of the 721 patients randomized (mean [SD] age, 61.4 [10.5] years; 53.1% male), 580 (80.4%) completed the trial. During the maintenance period, the rates of overall symptomatic hypoglycemia for insulin degludec vs insulin glargine U100 were 185.6 vs 265.4 episodes per 100 patient-years of exposure (PYE) (rate ratio = 0.70 [95% CI, 0.61-0.80]; P < .001; difference, -23.66 episodes/100 PYE [95% CI, -33.98 to -13.33]), and the proportions of patients with hypoglycemic episodes were 22.5% vs 31.6% (difference, -9.1% [95% CI, -13.1% to -5.0%]). The rates of nocturnal symptomatic hypoglycemia with insulin degludec vs insulin glargine U100 were 55.2 vs 93.6 episodes/100 PYE (rate ratio = 0.58 [95% CI, 0.46-0.74]; P < .001; difference, -7.41 episodes/100 PYE [95% CI, -11.98 to -2.85]), and the proportions of patients with hypoglycemic episodes were 9.7% vs 14.7% (difference, -5.1% [95% CI, -8.1% to -2.0%]). The proportions of patients experiencing severe hypoglycemia during the maintenance period were 1.6% (95% CI, 0.6%-2.7%) for insulin degludec vs 2.4% (95% CI, 1.1%-3.7%) for insulin glargine U100 (McNemar P = .35; risk difference, -0.8% [95% CI, -2.2% to 0.5%]). Statistically significant reductions in overall and nocturnal symptomatic hypoglycemia for insulin degludec vs insulin glargine U100 were also seen for the full treatment period. CONCLUSIONS AND RELEVANCE: Among patients with type 2 diabetes treated with insulin and with at least 1 hypoglycemia risk factor, 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of overall symptomatic hypoglycemia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02030600.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Wysham C, Bhargava A, Chaykin L, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017. PMID: 28672317. doi:10.1001/jama.2017.7117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。